Physician

Luko Michael Laptalo, M.D.

According to 2025 Medicare claims, Luko Laptalo, M.D. (NPI: 1114958501) practices hematology/oncology in the Sacramento-Roseville-Folsom, CA market, with the plurality of this provider's patient population coming from Sacramento, CA. This provider's primary affiliated billing organization is DIGNITY HEALTH MEDICAL FOUNDATION (NPI: 1700803418; TIN: 770359115) and primary practice location at 95816-3372. Laptalo is affiliated with the CommonSpirit ACO I (ACO ID: A2164), participating under the MSSP model.

Laptalo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 571 traditional Medicare patients, billed 60,395 HCPCS/CPT codes, and received $1,252,429 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,869 prescription claims across 284 beneficiaries totaling $4,522,446 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 40 claims. Open Payments data shows 3 records totaling $239. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,319,647 to $4,522,446. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,130 and ending at $1,018.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	483	48,361	$1,127,682
2016	446	59,010	$1,177,398
2017	540	55,548	$1,165,015
2018	564	78,705	$1,339,221
2019	584	69,051	$1,290,951
2020	567	71,375	$1,376,413
2021	576	84,792	$1,855,705
2022	546	72,959	$1,272,658
2023	565	67,441	$1,366,329
2024	571	60,395	$1,252,429

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	129	900	$1,319,647
2016	153	1,132	$1,390,453
2017	194	1,170	$1,699,441
2018	183	1,268	$1,813,980
2019	200	1,389	$2,202,142
2020	218	1,607	$2,656,716
2021	209	1,493	$2,997,051
2022	219	1,586	$3,679,872
2023	243	1,751	$4,538,730
2024	284	1,869	$4,522,446

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	40	$2,091
2021	N/R	35	$1,577
2022	N/R	N/R	N/R
2023	N/R	59	$12,290
2024	N/R	40	$1,284

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	47	57	$160
96413	Administration of chemotherapy into vein, 1 hour or less	46	171	$121
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	178	555	$108
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	311	520	$69
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	155	317	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	40	1,085	$550,126
Tagrisso	Osimertinib Mesylate	25	750	$451,322
Xtandi	Enzalutamide	27	810	$390,225
Imbruvica	Ibrutinib	21	610	$386,862
Piqray	Alpelisib	19	518	$364,712

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$1,058
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$239	Janssen Global Services, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Luko Michael Laptalo, M.D.?

Tedicare shows public-source Medicare data for Luko Michael Laptalo, M.D. (NPI 1114958501), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Luko Michael Laptalo, M.D. have ACO affiliation data?

Luko Michael Laptalo, M.D. is shown with ACO affiliation data for CommonSpirit ACO I (MSSP, ACO ID A2164).

What billing organization is linked to Luko Michael Laptalo, M.D.?

Luko Michael Laptalo, M.D. is linked to DIGNITY HEALTH MEDICAL FOUNDATION (billing NPI 1700803418) in the available physician profile data.

Does Luko Michael Laptalo, M.D. have Open Payments data?

Luko Michael Laptalo, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.